The ACR has long supported efforts to reduce drug prices through many of the provisions included in the House-passed version of the Build Back Better Act. However, the current wording of one provision puts patient access to Medicare Part B treatments at risk.
The ACR highlights essential information for providers for 2022 MIPS reporting in the 2022 Medicare Physician Fee Schedule Final Rule, published Nov. 2.
With a record-high 46 first-time contributors, this year’s matching campaign raised more than $26,000 from members and another $17,000 from volunteer leaders who made a pledge for each donor, advancing advocacy efforts on behalf of rheumatology.
The ACR will be working with the Senate as they consider and debate the important healthcare policies contained in this massive legislation.
The final rule, issued Nov. 2, finalizes many policies in the July proposed rule, including the decreased conversion factor, billing for shared visits and teaching services, the continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
If passed, the ACR-led resolutions will direct the AMA to advocate for state-level pharmacy benefit manager reform and to fix broken Medicare Administrator Contractor processes. Several other specialties joined the ACR’s resolutions as supporting cosponsors.
Selected ACR members will be invited to participate in a survey from the AMA Relative Value Update Committee. If you do, respond by the listed date. Data from these surveys helps set Medicare and other payer reimbursement rates.
Earlier this month, RheumPAC donors joined the Iowa representative, an ophthalmologist, for a virtual discussion about healthcare legislation and how it can help specialty providers and their patients.
New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis.
Professional practices, state societies and other organizations can support RheumPAC’s work with corporate funds through the RheumPAC Advocacy Fund.